Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

August 5, 2021

NASDAQ US Health Care Life Sciences Tools and Services earnings 58 min

Earnings Call Speaker Segments

Brian Blanchett

executive
#1

Hello, everyone, and thank you for being here on this call about our second-quarter 2021 earnings. Today we'll walk through the financial results that came out after the market closed, share some thoughts on our commercial activity, and then take your questions. If you haven't yet seen our earnings release, it's available in the Investor Relations area of illumina.com. With us from Illumina are Francis deSouza, our President and Chief Executive Officer, and Sam Samad, our Chief Financial Officer. Francis will speak about how Illumina's business is doing, and Sam will take us through the financial results. A recording is being made of this call, and the audio will be stored in the Investors section of our website. We intend for every forward-looking statement about our financial results and commercial activity that is made on today's call to fall under the protection of the Private Securities Litigation Reform Act of 1995. Risks and uncertainties apply to forward-looking statements. What actually happens or what results we achieve could differ materially from what is projected or discussed. Every forward-looking statement rests on information currently available, and Illumina takes on no obligation to update these statements. For a clearer picture of the risks and uncertainties that might make actual results come in differently, please look at the filings Illumina makes with the Securities and Exchange Commission — among them Illumina's latest Forms 10-Q and 10-K. With that, I'll hand the call over to Francis now.

Francis deSouza

executive
#2

Thanks, and good afternoon to everyone. Illumina’s Q2 revenues came in at $1.126 billion, which works out to 78% growth compared with a year earlier, handily beating what we had expected in every geographic region and market segment. Within our clinical markets—oncology, reproductive health, and genetic disease testing—we’re seeing expansion as reimbursement coverage widens, patient awareness rises, and additional sequencing applications make their way into the clinic. Population sequencing programs that are ramping up are adding to the strong growth in our research business. On top of that, genomic surveillance has become an essential instrument in the worldwide battle against the pandemic, and more than 70 countries are now relying on Illumina platforms for COVID-19 surveillance. Looking ahead, there’s momentum behind this worldwide surveillance infrastructure becoming the foundation of a lasting, global genomic epidemiology capability to take on future outbreaks, such as zoonotic transmissions, antimicrobial resistance, and bioterrorism. Q2 marked our second quarter in a row of record instrument sales, with revenue climbing 113% versus a year ago, and we closed the quarter with the biggest instrument backlog since NovaSeq was introduced. Now let’s turn to how we performed by platform. Our high throughput portfolio kept up its spectacular run, as NovaSeq posted its largest order volume since it launched in Q1 2017. Demand for high throughput sequencing capacity keeps growing, and more than half the orders in Q2 came from customers who are new to high throughput. What’s more, our customers continue to run these systems at a higher rate to keep up with demand in oncology testing, genetic disease testing, and population sequencing programs. Our mid-throughput platforms keep fueling growth, with record placements in Q2. The strength of the NextSeq 2000s, which deliver almost 3x the output of NextSeq 550, is opening up exciting new applications for customers such as Cold Spring Harbor Labs in single cell analysis. Clinical customers drove new NextSeq 550 placements. NextSeqDx once again set a record for shipments, as we observe a trend toward decentralization of clinical sequencing outside the U.S. Benchtop platforms also enjoyed an excellent quarter, with instrument revenue rising over 50% versus a year ago. We shipped more MiSeq instruments this quarter than in any prior quarter over the last 5 years; this record demand has come from our core business as well as emerging areas like preimplantation genetic screening and COVID surveillance. Turning to our Clinical and Research and Applied segments. Sequencing consumables revenue reached $704 million, up 82% compared with a year earlier, fueled by demand in both our Clinical and Research segments. Starting with our clinical business, our emphasis on market access and collaborations is broadening reimbursement, empowering new and existing testing providers, and benefiting patients around the world. There are now more than 1 billion covered lives globally across NIPT, WGS for RUGD, and CGP in oncology, which shows both the expertise and impact of Illumina’s market access team in driving coverage and the enormous opportunity in our clinical segment. Oncology testing, our largest market segment, posted its third quarter in a row of outstanding year-over-year growth as our customers announced additional offerings for therapy selection and MRD tests; in therapy selection, growing reimbursement for comprehensive genomic profiling is driving the shift from small to large panels. At this point, 74% of lives in the U.S. have coverage for CGP, and with further indications cleared, new customers are coming into oncology testing while established players such as Caris extend their reach. Our RUO comprehensive genomic profiling assay, TruSight Oncology 500, hit the 100,000 sample milestone during Q2 and has brought on more than 40 new customers this year so far, spanning 23 countries; on top of that, over the past year MRD testing has become a major growth driver for the oncology segment going forward, helped by favorable reimbursement decisions, a growing customer base and several approaches arriving on the market. Another exciting development is pharma's investment in MRD-based clinical trials aimed at bringing proven drugs into early-stage disease and improving outcomes for patients. Shipments of reproductive health consumables keep gaining from the updated ACOG guidelines. Back in January, our expectation was that NIPT would have coverage for roughly 3 million pregnancies in the U.S. by the close of 2021; that milestone has already been passed, and we anticipate coverage will keep widening. Outside the U.S. as well, we're advancing efforts so that every expecting family can obtain NIPT; take Germany, where national coverage is set to begin in 2022. On top of that, our CE-IVD marked VeriSeq NIPT solution continues to deliver growth across Europe and Asia. During Q2, Next Generation Genomic in Thailand brought in our VeriSeq NIPT Solution v2, widening access to expanded NIPT for expectant parents throughout Southeast Asia. Genetic disease testing posted yet another excellent quarter, fueled by reimbursement coverage spreading across Europe and falling sequencing prices, which are speeding the move from exomes to genomes. During the quarter, we additionally saw encouraging research and guidelines that acknowledge the diagnostic yield and cost effectiveness of whole genome sequencing in genetic disease. This June, Rady Children's Hospital together with the State of California released findings from Project Baby Bear, a pioneering program demonstrating substantial advantages of rapid whole genome sequencing in cutting both the time to diagnosis and health care spending for critically ill infants. Over 30% of these patients experienced a change in care because of the diagnosis that WGS made possible; this rapid whole genome sequencing protocol can now be accessed via Rady's expanding network of more than 60 hospital partners, along with other hospital networks nationwide. Shifting to our Research and Applied segments, growth was strong both year over year and sequentially. Momentum behind population genomics programs kept building in Q2; within the U.S., All of Us now runs at full scale, processing thousands of genomes each week. We likewise saw several initiatives scale up internationally, supplying a steady pipeline of new PopGen opportunities. From over 30 distinct PopGen initiatives, we anticipate revenue in the second half of the year. Multiomic, spatial and single-cell approaches are picking up momentum across many of our research segments, fueling high-intensity sequencing. Illumina's successful partnerships with firms including Olink, NanoString and 10x will make possible novel discoveries and broader applications reaching the clinic. With the Delta variant showing up, there's been fresh attention on and greater recognition of genomic surveillance as a tool against COVID-19 and pathogens that may come later. This quarter we launched the RUO 96-sample COVIDSeq assay and broadened the EUA for COVIDSeq on NextSeq 2000, which shows how we keep working to deliver the workflows, instruments and bioinformatics needed to address this. Right now, together with governments and testing labs, we're pursuing COVID surveillance programs across more than 70 countries. Those efforts pushed COVID consumable revenue higher in Q2 compared with Q1. As things stand, we anticipate consumable revenue across the second half staying roughly level with the first half. Our philanthropic work aims to make sure that nations facing big COVID surveillance needs yet lacking resources can still obtain our sequencers and consumables. Earlier this week, we said we would donate $1 million worth of sequencing capabilities, which includes 2 NextSeq 2000s, to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital; that will make COVID surveillance possible in Mumbai, the epicenter of India's devastating second wave. Before handing the call to Sam, I want to give a quick update on GRAIL. During Q2, GRAIL brought out Galleri, the first-of-its-kind multi-cancer screening test. We've offered this test to our own employees, and the positive feedback we've gotten is encouraging. Watching genomics deliver on its promise in oncology screening is exciting, and we back every company pursuing innovation in this area. As we said in late July, we're still committed to getting this pro-competitive deal closed, and we believe that with this acquisition, Illumina will hold a unique position to help save tens of thousands of lives; with that, I'll pass the call to Sam.

Sam Samad

executive
#3

Francis already walked everyone through it, but to recap, second-quarter revenue came in above what we had expected, up 78% from the same period a year earlier to $1.126 billion, powered by an 80% gain in sequencing and 57% growth in microarrays; and for the very first time since the company began, quarterly sequencing revenue on its own topped $1 billion, rising 4% on a sequential basis to $1.021 billion, which works out to 91% of total revenue. During the quarter, our core business accelerated across all regions, supported by clinical expansion and strong interest from research customers—a segment that the pandemic affected particularly severely in Q2 2020 and that continues to recover while increasing its sequencing work. Revenue from sequencing consumables increased 82% from the prior-year period, reaching $704 million, driven by record shipments of NovaSeq consumables, with solid demand powered by v1.5 flow cells. Sequencing instruments revenue grew 115% compared with the same period last year, totaling $189 million, representing one more quarter of substantial performance in every instrument category. Compared with the second quarter of 2020, NovaSeq shipments came in at over twice the level, with momentum from first-time high-throughput buyers. A new high was reached in mid-throughput system shipments, driven by record NextSeqDx shipments along with demand for NextSeq 1000 and 2000. New-to-Illumina customers have accounted for 25% of NextSeq 1000 and 2000 units since launch. COVID-19 surveillance testing revenue exceeded our forecast, contributing about $40 million in sequencing consumables revenue and $20 million in incremental instrument revenue. Sequencing service and other revenue also outperformed expectations, rising 41% year-over-year to $128 million, primarily due to roughly $20 million in onetime revenue recognized from NIPT royalties tied to a patent litigation settlement. Let's move to how each region performed. In the Americas, revenue reached $589 million, which was 76% higher than the same period a year earlier. The increase was driven by record sequencing product revenue, reflecting demand for clinical oncology testing as well as genetic disease testing. The region also benefited from momentum in genetic disease research stemming from population genomic initiatives, along with contributions from COVID surveillance testing. Turning to EMEA, revenue totaled $320 million, marking 90% growth compared with the prior year. Those results reflected a recovery in research together with quicker expansion in the clinical business, which included a record quarter for genetic disease testing, helped by momentum from broader market access and reimbursement. COVID surveillance testing contributed further to the region's strong performance. Turning to Greater China, we brought in $132 million there, which works out to 67% growth compared with the same period last year, and that came on the back of continued sequencing momentum with clinical expansion leading the way in that region. Shipments of sequencing instruments were more than twice what they were a year ago, and the reason is growing hospital demand for NextSeqDx, since Illumina sequencers offer better ease of use, accuracy and output quality. Then for APJ, revenue came to $85 million, up 67% year-over-year, and the growth was fueled by sequencing consumables across clinical applications in reproductive health and genetic disease testing, plus heavy use by research customers. Just as we expected, APJ revenue was down sequentially, reflecting the timing of fiscal year-end buying and the usual seasonality we see in Japan in the first quarter of 2021. Turning to gross margin and operating expenses, I'll focus on non-GAAP figures, which factor in stock-based compensation. I'd urge you to look at the GAAP reconciliation for these non-GAAP metrics, available in today's release and the supplementary data on our website. Non-GAAP gross margin came in at 71.8%, up 130 basis points from the prior quarter, largely driven by favorable utilization amid strong demand and onetime revenue tied to the patent litigation settlement; year-over-year, non-GAAP gross margin rose 320 basis points thanks to greater fixed cost leverage on higher volumes and a positive contribution from the patent litigation settlement, partly offset by product mix. On a non-GAAP basis, our operating expenses came to $471 million. That's up $51 million compared to the prior quarter, driven by compensation-related costs that were higher and more spending tied to projects. Even so, we finished under what we had projected, since some investments got pushed to later in 2021 — specifically, into the back half of the year. As we had expected, non-GAAP operating expenses rose $137 million from the same period a year ago. The reasons were increased costs for performance-based compensation, a larger headcount, and further investments to support our business growth. Our non-GAAP operating margin was 30%, compared with 32.1% in Q1 of 2021. Margins came in above our forecast thanks to stronger revenues and a favorable gross margin, which resulted from higher volumes along with the onetime patent litigation settlement. Non-GAAP other expense totaled $2 million, unchanged from the previous quarter and $15 million less than a year earlier, in line with what we anticipated. That decline compared with a year earlier was driven mostly by reduced interest income earned on short-term investments, since we shifted the makeup of our investment portfolio in preparation for paying for the GRAIL acquisition. Our non-GAAP tax rate came in at 17.9%, down from the prior quarter, because during the first quarter of 2021 we recorded a tax expense tied to certain earnings of foreign subsidiaries that are no longer indefinitely reinvested. The non-GAAP tax rate also decreased versus a year ago as a result of a larger share of earnings coming from jurisdictions where tax rates are lower. Turning to the second quarter, GAAP net income reached $185 million, equal to $1.26 per diluted share, and non-GAAP net income reached $276 million, equal to $1.87 per diluted share. Now moving on to cash flow and balance sheet items. Operational cash generation came to $253 million, and that figure reflects $105 million of continuation payments to GRAIL tied to the merger agreement. Days sales outstanding stood at 44 days, compared with 43 days in the prior quarter, a shift attributable to revenue linearity. Capital expenditures for the second quarter of 2021 totaled $44 million, while free cash flow reached $209 million. No common stock was bought back during the second quarter. We closed the quarter holding roughly $4.3 billion across cash, cash equivalents and short-term investments. In the second quarter, $491 million went toward repaying the outstanding principal on our 2021 convertible notes, which came due in June. The weighted average diluted share count for the quarter was about 147 million. Turning now to our 2021 guidance. For the entire 2021 fiscal year, our updated projection is revenue expansion somewhere between 32% and 34%, which works out to $4.28 billion up to $4.34 billion. If you take the midpoint of that guidance, it represents an increase of approximately $1.07 billion over 2020's result. Turning to the full 2021 period and applying the center point of the revenue outlook we just gave, we expect sequencing revenue in total to be up roughly 35% year over year, driven by two factors: growing momentum within our core business and stronger-than-expected contributions from COVID surveillance testing. Our expectation now is that non-GAAP operating margin for 2021 will come in at roughly 27.5%, which mirrors our improved revenue outlook along with our sustained dedication to ongoing innovation within R&D. Over time, we remain committed to enhancing operating margin leverage in our core business. We anticipate our non-GAAP tax rate will climb somewhere around 200 to 250 basis points versus the previous year, and that's above what we had been expecting; our updated outlook is for non-GAAP earnings per share between $6.30 and $6.50, with GAAP earnings per share between $4.69 and $4.89. Turning to the third quarter of 2021, revenue should be up roughly 30% compared with the same period a year ago. Non-GAAP earnings per share should land between $1.30 and $1.35, while GAAP earnings per share should fall between $1.23 and $1.28. At this point, I'll pass things back to Francis so he can share his closing thoughts.

Francis deSouza

executive
#4

Thanks, Sam. Our outstanding results for the first six months make it obvious that both Illumina and the people we serve are performing at peak capacity. Every one of our clinical markets is expanding: reimbursement has widened, so additional patients can obtain genomic tests that already exist, while new evidence brings fresh genomic uses into medical practice; when it comes to oncology, a greater number of cancer patients can now use CGP to guide therapy selection. What's more, tests for MRD and early cancer detection that are still emerging will fuel substantial growth in sequencing over the long term. With regard to genetic disease testing, the advantages rapid WGS delivers in how quickly diagnosis and treatment can happen are sparking greater awareness and uptake. As for NIPT, coverage has grown enormously across the U.S., yet considerable need remains abroad, which amounts to a huge opportunity for growth. Money for research and the total capital that investors are putting into life sciences remain remarkably strong, and that will propel innovation plus new sequencing applications for many decades ahead. Approaches such as single-cell, spatial and multiomic work on complicated challenges are producing research and clinical solutions that are bigger in scale and novel in nature. Because population genomics programs benefit national health systems, a growing number of governments are adopting such efforts, which extends sequencing's global reach even further. Through COVID surveillance efforts, the groundwork is being laid for an enduring worldwide infrastructure for genomic epidemiology. In these strides in genomics and human health, Illumina holds a central position. I take great pride in how our wonderful teams worldwide have executed; this moment is extraordinary for our field, and the technology road map now under development is the most thrilling one I've witnessed during my tenure at the company. It's a privilege to work with my colleagues toward fulfilling Illumina's vital part in bettering human health by unlocking the genome's power. I'll now ask the operator to begin the Q&A.

Vijay Kumar

analyst
#5

Nice results—congratulations. Francis, I'd like to begin with something about the outlook. For the back half, the revenue increase you're implying comes to roughly 20%, and that bar keeps rising by around 500 basis points; meanwhile you're describing a record instrument backlog, opportunities in surveillance, and so on. Could you discuss how revenue should trend in that period and why it might not end up being higher?

Francis deSouza

executive
#6

Sure, and thanks for asking, Vijay. Let me say up front that momentum across the company is tremendous, as you noted. Looking at each piece of what we do, those market segments are growing. Going into the latter portion of the year, our expectation is that this continues. Still, several items are on our radar. First—and Sam will give you additional detail—Q1 included some one-time items, and we don't anticipate those recurring in Q2, and we'll go through which ones they are. Second, the pandemic hasn't ended. Because of that, we're monitoring closely how the Delta variant unfolds within the U.S. as well as globally. That therefore—it means some restraint belongs in our expectations for what the business will deliver over the back half. Without question, we remain in the middle of the pandemic. Those two elements, I'd say, offset the incredible momentum we observe in the markets where we operate.

Sam Samad

executive
#7

Sure, Vijay — happy to give you a bit more detail on those one-time items from the first half, and thanks for asking. Things are going quite well for us, and momentum is building nicely in our main markets. That said, there are some one-time items from the first half that I should flag, since they matter when you're looking at the second half. Let me group those one-time items this way. First, in Q1 we saw roughly $20 million in stocking. No stocking showed up in Q2, though Q1 did include that $20 million. Second, I'd describe about $55 million tied to COVID surveillance instrument placements — that $55 million landed in the first half, and we don't expect it to recur in the second half, so that's one more item. Third, there's the U.K. Biobank, which ends and essentially concludes during the third quarter. That works out to roughly $30 million in additional revenues during the first half that won't be there in the second half. And last, there's a $20 million NIPT settlement from the second quarter that I mentioned during my prepared remarks, and it won't recur in the second half either. Adding all of that up, you get approximately $125 million of what I'd term one-time items in the first half that don't repeat. Strip those out of the first half and annualize, and essentially we're looking at a flattish second half relative to this first half.

Vijay Kumar

analyst
#8

Thanks, Sam — that helps. And Francis, if I can ask one more, your comment about box utilization going up caught my attention. Given those record placements in strong end markets and what the budget picture looks like, how should we frame fiscal '22? Do comps come into play, or should we connect the higher MRD numbers and the utilization remarks to get a sense of where consumables might land?

Francis deSouza

executive
#9

Sure. Let me start by saying we aren't prepared to comment on 2022 yet, though I can share additional detail on the trends we're observing. As you noted, the instrument side is performing very well throughout the portfolio. What makes this particularly thrilling, as you're aware, is that instruments usually serve as an early signal for the business, thanks to the model we use. And regarding my comments on instruments, our total backlog for them is the largest it has been since NovaSeq came out. When it comes to high throughput, order volume for NovaSeq reached its peak since the product's Q1 '17 debut. For mid-throughput, we're poised to nearly double how many NextSeqs we deliver. Considering what we've typically shipped over recent years, that's genuinely powerful momentum within the mid-throughput lineup. Even at the lowest end of the range, as I mentioned during my prepared comments, our MiSeq shipments hit their highest level for any quarter recently. So whether we're talking about low, mid, or high throughput, each of those segments is demonstrating genuine momentum, and that's what has built up the substantial backlog we're carrying into the back half of the year.

Doug Schenkel

analyst
#10

Thanks for that. What I'd like to start with is GRAIL; and I recognize that in your prepared remarks you mentioned you're still fully committed to GRAIL. It's reasonable, and not something people would dispute, to say that this process obviously isn't unfolding the way you had anticipated; and sadly, that's happening differently, though lately with PacBio, as you're well aware; so there are really 3 parts to this. First, it appears the regulators in the U.S. and EU could, tactically speaking, stretch this process out if that's their choice, and in a sense, attempt to let the clock expire across a period of 1 to 2 years. I realize that isn't what you're expecting or hoping for. But should that occur, would you be prepared to stay with this well into 2022? Then second, if this fails to complete, is the takeaway essentially that Illumina cannot buy any service company that depends on Illumina sequencing? And then third, what do you believe you could improve in your regulatory evaluation process going forward? And what changes are you making to your approach?

Francis deSouza

executive
#11

Great. I believe I've got all of those. So thank you, Doug, for asking them. So the first question is whether — would we be prepared to stay with this? And does it appear the process will let the clock expire? Let me walk you through how the schedule breaks down. Our agreement runs through December 20, so everything hinges on getting the green light from both the FTC and the European Commission before that date arrives. At this moment, several efforts are in motion. We've got our engagement with the FTC, we've got the Phase II review process with the European Commission, and separately there's activity in Luxembourg aimed at getting the European case thrown out on jurisdictional grounds. As things stand, any of these could reach a resolution, in one direction or another, before December 20. So at this point, we haven't yet hit the situation where time has run out. So right now, we're determined to see this through and get it finished. Our view hasn't changed that this transaction benefits competition. Our view also hasn't changed that tens of thousands of lives will be saved as a result — lives that wouldn't be saved without our purchase of GRAIL, purely because we're able to speed up the business. So, to give you an answer: we're committed to seeing this transaction through that window, through the close of the year. Don't take that to mean we're unable to acquire any other services provider, or anything else we might want to acquire. Over the past 18 months, we've completed a number of other acquisitions. So those deals have closed. And I think we'll keep hunting for opportunities that we believe create long-term shareholder value. If it turns out we need to bring those companies in through acquisition, then we'll keep looking for such opportunities from time to time. As for areas where improvement is possible? A key lesson we've picked up is this: obviously, we lack any Washington footprint, and nobody on our payroll is up on Capitol Hill sharing the Illumina narrative with the different agencies or with other people there. It has grown obvious to us that our footprint in that location needs to grow. That's why we've begun establishing that footprint. The wonderful part — and I personally have devoted far more hours over on Capitol Hill during these past 2 months — is that this narrative genuinely connects. So whenever we share it, what I mean is, folks truly rally behind it and are eager to champion it. Therefore, a lesson learned, and something we'll change going forward, is that our Capitol Hill footprint will expand, and the Illumina narrative will be shared by us with greater frequency and greater clarity.

Doug Schenkel

analyst
#12

Let me raise something with a longer horizon. When we look at the acquisitions that have happened lately in this area, plus the new companies that have gone public in sequencing, it appears reasonable to state that competitive forces will heat up our debt in sequencing across the coming years. More short-read platforms are on the way. Long-read tools will keep improving; that's already happening. And I believe you get it — and I want to put this as modestly as I can, since I'm someone who has concentrated heavily on sequencing for 15 years and watched many supposed technological threats appear and fade. When I survey the landscape and reach the conclusion that, hey, perhaps things feel somewhat different at this moment, perhaps that carries weight. So when you consider all that and truly consider the coming years, does the playbook stay the same? New instruments possibly arriving as early as next year, spanning the whole market from top to bottom, greater flow cell density, and basically riding the same elasticity curve just as you've done before? Or when we consider the coming years, is it somewhat different?

Francis deSouza

executive
#13

Fine. That's another excellent question. Let's begin with a few pieces of it. First, does it seem as though that competition is heating up at present in a manner it didn't previously? And second, given that, does the playbook remain unchanged when it comes to competing here? So let's take each piece. First, I'll say — and you'll understand this, with the 15 years you've spent watching this — we've consistently faced waves of competition, correct? A few years back, we'd have been discussing Qiagen and Thermo, and you were trailing in certain markets. So there have been — and since the market is so large and we remain at the very start of this enormous market, we absolutely expect it will keep drawing a great deal of venture investment. I mean there are dozens of companies; and we could have had this conversation at any point during the last decade. And I'd have said to you there are dozens of companies receiving funding to pursue the sequencing space. So I don't particularly notice a change when it comes to how many companies are being started. The specific competitors that emerge differ, clearly, each time. And I like what you wrote in one of the notes I read from you, Doug, where you said the trail is literally the dead bodies of people whose sequencers look great on PowerPoint, but a couple of years away from launch, could never get closer than that to launching. So we've witnessed that. Now we will see more competition, though, going forward. Again, we expect that. The part of the playbook is the same. When it comes to accuracy, offering better and faster sequencing remains the benchmark, and we keep up an unyielding tempo on the innovation front that rivals are compelled to match, plus we establish the market's price level that everyone else must match as well. Those elements of how we compete won't change. Something else that stays the same is that we keep piling on additional value for our customers who buy sequencers. You've watched us accomplish this with Edico, through the hardware acceleration that is now integrated inside a sequencer. You've watched us accomplish this by broadening the bioinformatics pipeline that is now integrated inside a sequencer; therefore we keep widening what it means to build a sequencer; and you recall the shift we made from what our sequencers produced being images, which then turned into base calls; and at present, from our sequencer, you're able to obtain variants, which no one else in the market offers. And at present we'll compel every other player to respond to that by saying you now need to add that secondary pipeline to your sequencer in order to keep up with Illumina providing you variants. Yet a portion of how we compete has shifted. The genomics sector and Illumina's operations are far more diversified than at any prior point, correct? Several years back, we were aiming at the research sector. And it was truly one instrument, the HiSeq, right following the GA before it. So what you sold were kind of the top throughput sequencers into the RUO, the research sector. At present, that represents merely one segment of our operations; thus our operations have genuinely diversified. Close to 44%, 45% of our operations originate from the clinical sector while the remainder is research and applied. Over half of our operations originate from beyond the U.S. And we possess numerous cleared end-to-end workflows available in the market; therefore when I assess the landscape, there isn't a single rival out there that covers all those segments of the operations; thus every one of them has their own distinct kind of approach; sometimes, when you must provide clear end-to-end workflows, sometimes, it's better, faster, cheaper; therefore that's a distinction. I believe there is no single rival I can examine, Doug, and claim that rival is pursuing the bulk of our operations.

Tycho Peterson

analyst
#14

Francis, let's return to the guidance topic. When I consider the pluses and minuses during the latter half of this year regarding COVID, particularly with respect to certain PopSeq initiatives, I'm curious how you assess the danger to the ones already underway? Then regarding surveillance, during the prior quarter you mentioned you anticipated zero instruments. Yet you ended up with a few instruments in this quarter. So should we conclude that perhaps the tail on the instrument side for surveillance might actually be underestimated?

Francis deSouza

executive
#15

Let me break your question into 2 sections. I'll begin with PopSeq, then move on to COVID instruments. Regarding COVID — regarding the PopSeq initiatives, our current position makes us quite pleased. As I mentioned, the U.K. Biobank keeps pressing ahead at maximum capacity. We anticipate it will wrap up near the close of this year, yet it remains sequencing at full production scale. All of us is currently sequencing at full production scale as well. We discussed processing thousands of samples each week; that pipeline appears quite strong. And unless something dramatically unforeseen occurs with all of us, I don't anticipate significant interruption throughout the year. So they have been performing quite well. Another genuinely thrilling aspect of PopSeq is that we now have 30 initiatives operating across the globe; this means the revenue contribution from PopSeq initiatives is beginning to diversify as they ramp up worldwide. In my view, that provides us somewhat greater resilience, because if one region experiences more impact than another, plenty of other regions will still proceed. So for the remainder of the year, I believe the PopSeq setup is quite solid. On the subject of COVID instruments, you are correct. A few months back, while I was on this call, I informed you we anticipated no additional instruments for the year; we believed the purchase would occur in Q1. Then surprisingly, during Q2 we sold a number of instruments for COVID surveillance. Honestly, Tycho, that segment of the business is difficult to forecast. Therefore, what we have incorporated into the model is zero additional instruments for the remainder of the year plus $50 million to $60 million for consumables. And certainly, it is entirely possible that people purchase additional instruments; however, once again, that is difficult to forecast.

Tejas Savant

analyst
#16

Francis, I'd like to ask a quick follow-up about PopSeq, and after that I have something on China. Regarding PopSeq, there seems to be some chance of a hold-up when it comes to the MVP renewal. Clearly, that has brought in significant revenue for you over the years. How much danger is there that a bit of a gap could appear as some of your bigger customers move into 2022? Then, about China, there was news lately concerning fresh buy-Chinese targets put out by the government for hospital buying. Do you have any view on how that might affect your growth? Clearly, NextSeqDx, after getting regulatory clearance there, has been a major growth engine for you in that market.

Francis deSouza

executive
#17

Yes. Thank you, Tejas. Let's take those 2 questions in turn. Because of what I just mentioned, the reality that we now have a number of PopSeq programs, and several of the larger ones are already operating at scale. Our confidence in the PopSeq pipeline and the revenue pipe for the remainder of the year is quite high. So we've examined whatever risks might be tied to them. We've examined the timing. Still, our confidence is high, given the variety of revenue sources and the pop-gen pipeline. On China, the performance we've been observing there has made us quite pleased. We've discussed the growth we're seeing in China. We continue to hold our leading position in China. Our approach in that country is truly delivering results, and it connects to what you raised; we have at all times pursued a strategy in China that was highly partner-centric. As a result, we have partners who build their products on our instruments and sell those products to customers. And those customers are — those partners are Chinese partners. Consequently, many of them qualify even under the Made in China regulations. That places us in a very strong position in China. Another point — actually a couple more points, one of which you brought up, namely the NovaSeqDx, again, a partner model of sorts, yet that represents a very encouraging move forward for us in China. And the rules regarding LDTs in China are likewise quite favorable in terms of what they mean going forward; so the growth makes us happy. Some of what we're seeing encourages us, in terms of indicating positive momentum ahead.

Sam Samad

executive
#18

And Tejas, one more point I might make regarding population genomics — both for the back half and continuing on a steady basis as we move through 2022 — is that what's genuinely thrilling about these initiatives right now is exactly what we mentioned before: roughly 30 population genomics programs that are fueling contribution during the latter six months and after. So in that regard, I'd describe us as quite well diversified, with the contribution distributed among a number of them that are already underway; these aren't efforts we're sitting around waiting to materialize — they're actively in motion and beginning to generate contribution; and then there are the big ones we've discussed, including the U.K. Biobank, which is finishing up in the second half.

Derik De Bruin

analyst
#19

I've got a few things to ask. First off, I'd say those instrument figures are really impressive, and so is what was said about the backlog. Francis, how do you think about launching new products? What I mean is, it seems like there's still plenty of room left for NovaSeq. And I recall — either earlier, or maybe I should say last year, or was it sooner this year, you surely remember we discussed the possibility of a next-generation NovaSeq or something along those lines, back when the 3 was coming out and so forth. Given how strong the current portfolio is, what's your thinking these days on bringing out new products?

Francis deSouza

executive
#20

That's a really good question. Part of how we approach this, Derik, hasn't shifted, though one aspect actually has, and I'll walk you through both. What remains the same is this: we bring products to market at the point when we believe the market is prepared — that is, ready to take on the price points — and we'll tap into further elasticity and expand the overall market; so we keep talking with our customers to get a sense of where the demand curve sits. And once we see a chance to grow the market by releasing an instrument at a particular price point or with a particular capability, that's the moment we introduce the product. So our technical groups are always advancing the technology; and once we sense the market is set, we do the engineering work to turn those technologies into a finished offering; that side of the philosophy is unchanged, and we'll keep monitoring for the right moment to spark a market segment with a new product. What's different, and honestly it's fascinating, came from observing what unfolded with NextSeq 1000, 2000. What we've observed with NextSeq 1000, 2000 is that the 1000, 2000 has hugely grown the mid-throughput market. It wasn't merely an upgrade or a replacement cycle. It's really striking, in fact. When you consider how many mid-throughput instruments we've shipped across the past several years, that figure has stayed pretty consistent. This year, we're on pace to nearly double it. And plenty of people are still purchasing 550s and 550Dxs. What's occurred is that we've sparked and unlocked new markets for the mid-throughput instrument through the price points we've introduced with the 1000, 2000. And that differs from how the Genomics market has operated previously; so now we see a chance, even within a market segment, not only to spark an upgrade cycle, but to genuinely open up other portions of that segment with an offering in that market segment. And that's a different philosophy we're now incorporating into our strategies as we consider products down the road.

Derik De Bruin

analyst
#21

Excellent, that's a big help. Sam, you didn't provide us with any kind of pull-through figures for the installed base — for your instruments. Could you give us some detail there, in particular what NovaSeq's pull-through was, plus NextSeq's and MiSeq's?

Sam Samad

executive
#22

Absolutely, Derik. Yes, glad to; when it comes to NovaSeq, the most recent guidance we provided was $1.1 million to $1.2 million for each instrument, and we indicated we'd land at the upper portion of that. So I can tell you that during Q2, we came in above it; and at this point our outlook for the entire year is that we'll be beyond that range — the $1.1 million to $1.2 million — we're going to go past it. So we aren't handing you a precise figure, but we were going to be over that $1.2 million ceiling. As for NextSeq, the pull-through for NextSeq 550, at least, we haven't disclosed any pull-through for NextSeq 2000 or 1000, since it's too early in those instruments' life cycle to give that; but for NextSeq 550, we're at the upper portion of that 100 to 150 range we've historically disclosed; so pull-through sits at the top of it. As for MiSeq, we're inside the 40,000 to 45,000 pull-through range for that instrument; and as for MiniSeq, we're inside that — at the upper portion of the 20,000 to 25,000 pull-through range for that instrument.

Dan Arias

analyst
#23

Francis, following up on what you said about market readiness and the position of your customer base — do you have any sense of how many of your NovaSeq customers are actually using the $600 genome offering right now? And I suppose the bigger question is whether you're able to tell us that if you do know.

Francis deSouza

executive
#24

Good question. When it comes to a specific percentage, I can't put a figure on it or tell you how I'd break that down. What I can say is that the price cut we brought to market last summer, the one that sparked the elasticity we've been seeing, means the $600 genome is available fairly widely now across our NovaSeq customer base. So my expectation is that a meaningful share of them are in fact taking advantage of that price. Of course, as you're aware, genomes aren't always what they're running. These days NovaSeqs get used across a very wide set of applications, and there's a lot of NovaSeq usage in oncology — for TSO 500 or some of those large panels. Still, I'd say many of them, a significant percentage, can run those applications at a price point like that, though an exact figure isn't something I can provide.

Dan Arias

analyst
#25

Alright. On the cancer front, perhaps, a portion of the efforts we've completed demonstrated quite a robust reaction when it comes to how AmpliSeq gets used with Illumina machines. My assumption, or rather my question, I suppose, is how essential do you view that collaboration for your oncology business moving forward? Also, could there be any margin effects significant enough to mention, or that we ought to keep in mind?

Francis deSouza

executive
#26

Yeah. How I look at it is, I would say, having it as a piece of the portfolio is good, yet it isn't an essential piece of the portfolio. Regarding even considering the revenue for us, I wouldn't treat that as a major portion of the revenue we generate in the oncology business whatsoever. The motive behind doing it is we want to ensure our customers can access the widest choices regarding what they wish to pursue, yet it isn't a significant contributor to our revenue in oncology.

Patrick Donnelly

analyst
#27

Francis, and this one may really be for Sam. I'm curious about how the pace evolved across the quarter, and how activity ramped up? Then especially over the final few weeks, or quarter to-date, has there been any deceleration or customers pulling back lately because of Delta? I'm simply attempting to understand lab activity as it moved along through the quarter and, once more, especially in recent days?

Francis deSouza

executive
#28

Yeah. Let me begin with what's straightforward. At this moment we aren't observing any deceleration. Owing to Delta, no shutdowns are showing up. Everything came in quickly, Patrick. If I — what I mean is you can observe it through, I believe, our DSO, as you noticed linearity got better even during this quarter. Internally it felt like the quarter opened quickly and then accelerated. So once more, nothing slowed down midway. Yet what stood out again was how really fast the start was; therefore the late surge, I would say, wasn't quite so dramatic since we had such a quick beginning to the quarter.

Sam Samad

executive
#29

Correct. If you look at — Patrick, regarding — one additional thing about what you asked, no, that deceleration did not occur, as Francis mentioned. We remain in a year shaped by COVID, and Delta is clearly still spreading fiercely. So when we consider the back half, we're still of course accounting for what any closures and so forth might do; however, right now, that isn't showing up. And the quarter finished really powerfully, just as it began.

Patrick Donnelly

analyst
#30

That's useful. Now perhaps a single question regarding NextSeq. What I mean is it keeps going — appears to be one record quarter following another there. Could you describe what you're observing when it comes to clinical demand for it? How much did it rise this quarter compared with the prior quarter, and what are your expectations looking ahead?

Francis deSouza

executive
#31

Yes. What I mean is this has been a fairly extraordinary story. I believe I brought it up a few minutes back. When you consider how many instruments we ship within that segment, it's currently nearly twice as many as what we historically sent into that segment. So a handful of points I'll highlight. First, we keep shipping 550s and 550Dxs. So there are customers who validated workflows on those instruments, and they keep purchasing. We're observing a solid count of new to Illumina and new to that segment customers arriving. It remains among the clinical workhorses in our portfolio, and you observe applications in oncology, you observe applications in NIPT, and that remains the case. The items we discussed regarding the expansion we're witnessing in the clinical market, all that reimbursement that began last year for oncology, for NIPT, all of that is fueling the instrument purchases we're seeing. And that's a truly excellent sign because, as we discussed, instrument purchases for us serve as a lead indicator of future growth; and so when you place that many instruments, it's thrilling for us to consider. And so those are a few things that they are driving the mid-throughput.

Sam Samad

executive
#32

Maybe I can add another data point on adoption and what it looks like across customer types—or actually not by customer segment, but just in terms of where those placements come from. Roughly 25% come from people who are new to Illumina and are picking the NextSeq 2000 and 1000, which is pretty encouraging. Basically, new-to-Illumina buyers are expanding the pie; we're also seeing around 30% come from benchtop users. Those are customers who were previously on MiSeq or MiniSeq and are now stepping up to NextSeq 2000, 1000. And we're seeing capacity upgrades as well, along with NextSeq 550 conversions moving to 2000, 1000. Still, like we've said, the NextSeq 550 and 550Dx is really holding up very well, with continued placements in those categories. What we aren't seeing is customers really picking NextSeq 2000 instead of NovaSeq; so that's something we've always said we didn't expect, and we aren't seeing it. If anything, only a genuinely very, very small number of customers have done that—about $19 million worth.

Kyle Mikson

analyst
#33

Because time is limited, I'll pose a handful of questions and then silence myself. First, regarding that $90 million — you recall, the CDC funding tied to the pathogen centers of excellence — when might that become a favorable push for Illumina, considering the results anticipated in August of '22? That's my initial question. My second one concerns the spatial and proteomics readout. I'm curious whether that will serve as a meaningful growth engine, I suppose, moving forward. Is it making a difference in your view? And then, on the timing of COVID surveillance testing plus the guidance covering the year's second half — perhaps, Sam, could you address that briefly?

Francis deSouza

executive
#34

Sure. I'll begin, then hand things over to Sam. Regarding the CDC funds, the American Rescue Plan Act, and all those dollars, we are monitoring how distribution of that money unfolds. We have not actually incorporated much of it into what we anticipate across this year, since decisions remain about the way those funds get parceled out. We do anticipate receiving some upside from it as we move into subsequent years, though we haven't included much, and Sam can add further detail. Spatial and proteomics certainly hold promise. They are clearly nascent; they might be comparable to where single cell stood several years back, and single cell today contributes far more to our business than spatial or proteomics do. Still, with the level of enthusiasm surrounding both areas, we anticipate they will drive growth for our business in the future.

Sam Samad

executive
#35

Alright, so starting with the American Rescue Plan and a portion of the money allocated there — the $1.7 billion, with $400 million directed toward those centers of excellence, and of that, $90 million has been allocated so far. But how it actually gets distributed won't really be settled until August of '22. For our business, I'd characterize that as a longer-term gain that we anticipate. So that's what we see as the lasting genomic epidemiology advantage — the infrastructure being established — which we view as a clear potential upside in years ahead, not in the current year. Regarding this year, Kyle, to lay out the progression as it relates to the guide: in Q1, we recorded $55 million, composed of $35 million instruments and $20 million consumables. In Q2, we recorded $60 million, with $20 million instruments and $40 million consumables. And for the second half, our expectation is roughly $50 million to $60 million of sequencing consumables revenue; we see that as evenly divided between Q3 and Q4. That's above what we had guided to on the Q1 call, simply driven by the additional utilization and placements we're observing in the first half.

Brian Blanchett

executive
#36

We appreciate you sending those in. Just a quick note — you’ll be able to hear this call again through the Investors area on our site, and the details for calling back in are included in the earnings release we put out today. Thanks for being with us; that brings today’s call to an end, and we’re eager to share our next update once the third fiscal quarter of 2021 has wrapped up.

Operator

operator
#37

And that concludes today's conference. Thank you all for joining. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.